跳至主要内容
临床试验/CTRI/2023/04/051364
CTRI/2023/04/051364已完成Unknown

A randomized, double blind, placebo controlled, parallel group study to evaluate the efficacy of UP165 on sleep quality and mood state in healthy adults

Vedic Lifesciences Pvt. Ltd0 个研究点目标入组 175 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
已完成
入组人数
175

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Male and female subjects =20 and = 60 years’ old with moderate physical activity level as per International Physical Activity Questionnaire – Short Form (IPAQ - SF)
  • Volunteers with body mass index between 18.5 and 29.9 kg/m2.
  • Fairly bad or very bad subjective sleep quality with a score of 2 or 3 assessed as per PSQI Q9.
  • Willing to maintain current dietary pattern, activity level, and stable body weight for the duration of the study, and refrain from any drastic lifestyle changes.
  • Unable to fall asleep or unable to stay asleep (2 or more waking episodes during sleep at least twice a week but not more than four times)
  • Agrees to maintain current sleep schedule throughout the study
  • Agrees to stay in the current time zone for the duration of the study
  • Subjects ready to give voluntary, written, informed consent to participate in the study.
  • Willing to complete all study procedures including study-related questionnaires and comply with study requirements.

排除标准

  • Subjects diagnosed with sleep disorders secondary to another health problem.
  • Consumption of hypnotic drugs ( <3 months before inclusion).
  • Subjects with a history of caffeine consumption post 6:00 pm.
  • Individuals taking any other sleep supplements and are unwilling to stop taking those supplements for the duration of the study period
  • Recent history of physical, emotional, social trauma within last three months.
  • Participants who are not medication (which are likely to impact sleep quality or pattern) free for at least 4 weeks apart from contraceptive pills
  • Subjects who consume pain-relieving medications more than once per week.
  • Individuals who have night terrors regularly
  • Individuals who regularly sleepwalk
  • Individuals who work at night shifts.
  • Individuals who have regular bad dreams
  • Use of the following medications during the study period: oral or injectable corticosteroid, sedating antihistamines (e.g. cold, allergy, motion sickness), psychotropic medications or hypnotics, benzodiazepine, narcotics, any illicit drugs
  • Gastro-intestinal, hepatic, respiratory, psychiatric, kidney, or cardiovascular disorder ( <3 months before inclusion),
  • Recent ( <3 months before inclusion) change in lifestyle (food, body weight, sport, drug, and/or dietary supplement),
  • Students having regular class and assignments
  • Subjects addicted to digital media who exhibit at least five of the following symptoms currently:
  • i) Preoccupation with the digital media use
  • j) Withdrawal symptoms that occur when digital media use is not possible
  • k) Build-up of a tolerance that requires increasing amounts of digital media use to satisfy cravings
  • l) Unsuccessful attempts to stop or limit digital media use
  • m) Replacement of previously pleasurable activities with digital media use
  • n) Unwillingness to stop digital media use despite its negative consequences
  • o) Being deceptive about digital media use
  • p) Using digital media use as a coping mechanism
  • Addiction or history of substance abuse,
  • Consumption of more than 3 glasses of alcohol per day,
  • Pregnant or lactating woman,
  • Lifestyle habits which would modify the wake-sleep rhythm, or which was expected to be modified during the study period (e.g., night work), and finally,
  • Known allergy to the IP.

研究者

相似试验

进行中(未招募)
1 期
Investigate the safety and efficacy of study drug ABX464 compared with placebo in patients with moderate to severe ulcerative colitis who have failed to other treatments.Moderate to Severe Ulcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10066678Term: Acute ulcerative colitisSystem Organ Class: 100000004856
EUCTR2018-003558-26-CZABIVAX232
进行中(未招募)
1 期
Investigate the safety and efficacy of study drug ABX464 compared with placebo in patients with moderate to severe ulcerative colitis who have failed to other treatments.Moderate to Severe Ulcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10066678Term: Acute ulcerative colitisSystem Organ Class: 100000004856
EUCTR2018-003558-26-HUABIVAX232
进行中(未招募)
不适用
A randomized, double blind, placebo controlled, parallel-group study to determine the effect of BXL-628 in post-menopausal women with Overactive Bladder (OAB)
EUCTR2004-000609-23-ITBIOXELL SPA
进行中(未招募)
不适用
A randomized, double blind, placebo controlled, parallel group trial for assessing the clinical benefit of Dronedarone 400mg BID on top of standard therapy in patients with permanent atrial fibrillation and additional risk factors - Permanent Atrial fibriLLAtion outcome Study using Dronedarone on top of standard therapy (PALLAS)MedDRA version: 12.1Level: LLTClassification code 10003658Term: Atrial fibrillationAtrial Fibrillation
EUCTR2010-019791-73-SKSanofi-aventis recherche & développement10,800
已完成
不适用
A clinical study to find The safety and efficacy of Asafin in patients suffering from dyspepsia
CTRI/2018/01/011149Akay Flavours and Aromatics Private Limited60